This study is really relevant to people with Type II diabetes. Type II are typically not "insulin dependent", some are, but most Type II can be treated through exercise, diet and other drugs. Not that its completely wiped away, its just very different from Type I. I think the average person is unfamiliar with the difference between Type I and II.
I do not believe this infringes on Insulet's market whatsoever and investors should not be concerned. Its probably more concerning for pharma working on other drugs to reduce the impact of Type II (insulin resistance).